The tweet was deleted by the author.
But we saved everything 🙂.
Biogen is presenting new data for an investigational medicine for cutaneous lupus erythematosus at AAD 2026.
The company says this effort is part of its ongoing work to develop a potential new option for people with this serious form of lupus.
View post on X Loading...
BIIB is currently trading at $183.84, which is below both the MA-20 ($185.80) and MA-50 ($184.80), suggesting near-term and medium-term bearish pressure, while still well above the MA-200 ($158.20), indicating long-term support remains intact. The Ichimoku Kijun level on D1 is $189.53, acting as immediate resistance above the current price, while near-term support sits at MA-100 ($178.91) and key support is reinforced by MA-200 ($158.20); near-term resistance is at MA-20 ($185.80), with the key resistance at the Ichimoku Kijun ($189.53).
Momentum indicators on D1 show a firmly negative bias, with MACD signaling strong sell and ADX at a subdued 10, pointing to weak trend strength. RSI at 47.19, Stoch RSI at 28.97, and CCI near neutral all suggest modest downside momentum but not significant oversold conditions, while BBP at 5.21 indicates sellers are currently dominant in the intraday dynamic. AO stands neutral, not reinforcing the prevailing downward momentum. BIIB has risen $2.38 (1.31%) over the past week, now at $183.84, up from $181.46 a week ago, with the price positioned in the lower part of this week’s range and weekly volatility at 6.63%. The weekly tone has been mixed, showing consolidation after failing to hold the high, and in today's session, the stock experienced a noticeable drop of 3.78%.
Looking ahead, the expected price range for BIIB over the next week is $179.80 to $189.50, which sits comfortably above the 52-week low of $110.04 but below the 52-week high of $202.25. Based on W1 signals (RSI, ADX, MACD, MA-50), the probability of a price increase is very high (more than 80%), making a decline less likely. The baseline scenario sees BIIB moving sideways between $179.80 and $189.50. A bullish scenario would unfold if the price breaks above $189.50, opening a path toward higher resistance, while a bearish scenario would see a dip below $179.80, potentially targeting the MA-100. The yearly context shows the stock maintaining a strong position above its yearly midpoint, favoring buyers if long-term supports continue to hold.
Previously it was reported that Biogen and Eisai released new real-world data on early Alzheimer's disease treatment persistence, with analysts highlighting mixed technical momentum but a supportive longer-term outlook for the shares. As attention now shifts to Biogen's upcoming milestones, traders should monitor for any shifts in pipeline or commercial developments that could serve as catalysts for renewed price momentum.